Evidence map›Paper›PMID 41171885›Full record

ArticlePLoS pathogens2025

Mycobacterium tuberculosis triggers reduced inflammatory cytokine responses and virulence in mice lacking Tax1bp1.

Jeffrey Chin, Nalin Abeydeera, Teresa Repasy, Rafael Rivera-Lugo, Gabriel Mitchell, Vinh Q Nguyen, Weihao Zheng, Alicia Richards, Erica Stevenson, Danielle L Swaney and 4 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jeffrey ChinDepartment of Medicine, University of California, San Francisco, California, United States of America.
Nalin AbeydeeraDepartment of Medicine, University of California, San Francisco, California, United States of America.
Teresa RepasyDepartment of Molecular and Cell Biology, University of California, Berkeley, California, United States of America.
Rafael Rivera-LugoDepartment of Molecular and Cell Biology, University of California, Berkeley, California, United States of America.
Gabriel MitchellDepartment of Molecular and Cell Biology, University of California, Berkeley, California, United States of America.
Vinh Q NguyenGladstone-UCSF Institute of Genomic Immunology, San Francisco, California, United States of America.
Weihao ZhengDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, California, United States of America.
Alicia RichardsQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, California, United States of America.
Erica StevensonQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, California, United States of America.
Danielle L SwaneyQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, California, United States of America.
Nevan J KroganQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, California, United States of America.
Joel D ErnstDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, California, United States of America.
Jeffery S CoxDepartment of Molecular and Cell Biology, University of California, Berkeley, California, United States of America.
Jonathan M BudzikDepartment of Medicine, University of California, San Francisco, California, United States of America.ORCID 0000-0001-8025-7911

Funding

The role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5M
Virus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENNER, CHRISTOPHER W · 2013 to 2017
$26.0M
RESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Melanie Maria Ott · 2018 to 2026
$21.4M
Host-Directed Strategies to Create Synergistic Antibacterial TherapiesDP1AI124619 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COX, JEFFERY S · 2015 to 2019
$3.9M
Discovery of novel, ubiquitin-regulated mechanisms of TB control by macrophagesR01AI120694 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COX, JEFFERY S, KROGAN, NEVAN J · 2015 to 2019
$3.3M
Tuberculosis Research and Mentorship Program (TB RAMP II)R25AI147375 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Elizabeth Fair, PAYAM NAHID · 2020 to 2026
$2.8M
Using proteomics to identify host cell death factors during M. tuberculosis infectionR01AI194696 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jonathan M Budzik · 2025 to 2026
$1.6M
Deciphering the role of autophagy receptor phosphorylation and host kinases in the targeting of M. tuberculosis to autophagyK08AI146267 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUDZIK, JONATHAN M · 2019 to 2023
$995k
NIAID NIH HHS DP1 AI124619NIAID NIH HHS K08 AI146267NIAID NIH HHS P01 AI063302NIAID NIH HHS R01 AI120694NIAID NIH HHS R01 AI194696NIAID NIH HHS R25 AI147375NIAID NIH HHS U19 AI106754NIAID NIH HHS U19 AI135990
6 · The paper itself

Abstract

Host responses - autophagy, cell death, and inflammation - limit the growth of bacterial pathogens while minimizing tissue damage. During the early stages of infection, Mycobacterium tuberculosis (Mtb) thwarts these and other innate immune defense mechanisms in alveolar macrophages (AMs) derived from the yolk sac; in later stages, it circumvents defenses in recruited mononuclear cells (MNCs) and survives within them despite additional cytokine stimulation from recruited T cells. The mechanisms that drive variable rates of Mtb growth in different macrophage subtypes and how Mtb manipulates inflammatory responses to grow within innate immune cells remain obscure. Here we explored the role of the host factor, Tax-1 binding protein 1 (Tax1bp1), an autophagy receptor that targets pathogens for degradation through selective autophagy and terminates pro-inflammatory cytokine responses. Unexpectedly, we found that Tax1bp1-deficient mice were less susceptible to Mtb infection, and generated reduced inflammatory cytokine responses, compared to wild-type mice; the same mutant mice exhibited decreased growth of, and inflammatory cytokine responses to, Listeria monocytogenes, suggesting that Tax1bp1 plays a role in host responses to multiple intracellular pathogens. Contrary to our previous ex vivo findings in bone marrow-derived macrophages (BMDMs), in vivo growth of Mtb in AMs and a subset of recruited MNCs was more limited in mice lacking Tax1bp1 relative to wild-type mice. To better understand these differences, we performed global protein abundance measurements in mock- and Mtb-infected AM samples ex vivo from wild-type mice. These experiments revealed that Tax1bp1 protein abundance does not significantly change early after infection in AMs but does in BMDMs; moreover, early after infection, Tax1bp1-deficiency reduced necrotic-like cell death -- an outcome that favors Mtb replication -- in AMs but not BMDMs. Together, these results show that deficiency of Tax1bp1 plays a crucial, cell type-specific role in linking the regulation of autophagy, cell death, and anti-inflammatory host responses and overall reducing bacterial growth.

Indexed as

CytokinesIntracellular Signaling Peptides and ProteinsMycobacterium tuberculosisTuberculosisAnimalsAutophagyImmunity, InnateInflammationListeria monocytogenesListeriosisMacrophages, AlveolarMiceMice, Inbred C57BLMice, KnockoutMinor Histocompatibility AntigensNeoplasm ProteinsCytokinesIntracellular Signaling Peptides and ProteinsMinor Histocompatibility AntigensNeoplasm ProteinsTAX1BP1 protein, mouse

Identifiers

PMID41171885
PMCPMC12588459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.